(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/213923 A1

(51) International Patent Classification:
A61K 31/4192 (2006.01) *A61P 43/00* (2006.01)
A61K 9/28 (2006.01)

(21) International Application Number:
PCT/EP2021/059943

(22) International Filing Date:
16 April 2021 (16.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2020/060940
19 April 2020 (19.04.2020) EP

(71) Applicant: **IDORSIA PHARMACEUTICALS LTD** [CH/CH]; Hegenheimermattweg 91, 4123 Allschwil (CH).

(72) Inventors: **BRAUNSTEIN, Guy**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **PAIN, Scott**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **SEBOEK-KINTER, Dalma**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **VAILLANT, Cedric**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH).

(74) Agent: **VELKER, Jörg**; Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: MEDICAL USE OF DARIDOREXANT



(I)

(57) Abstract: The invention relates to daridorexant: Formula (I) or a pharmaceutically acceptable salt thereof such as especially the hydrochloric acid salt; for use in a method of treatment of sleep disorders such as especially insomnias, wherein daridorexant improves daytime performance, especially reduces daytime sleepiness associated to such sleep disorder

WO 2021/213923 A1